Late stage O-glycosylation: A strategic gateway to complex therapeutic natural products.

Late-stage O-glycosylation has rapidly evolved into a paradigm-shifting strategy for the total synthesis of architecturally complex and pharmacologically privileged natural products. Unlike early-stage glycosylation, which is often constrained by protecting-group manipulations and linear synthetic planning, late-stage installation of glycosidic units offers unprecedented flexibility, enabling chemists to directly fine-tune biological performance at advanced synthetic stages. By strategically appending glycosyl residues onto fully elaborated aglycone scaffolds, this approach allows for rational modulation of solubility, metabolic stability, cell permeability, and target selectivity-properties that dictate clinical success yet are notoriously difficult to optimize through conventional synthetic modifications. This chapter highlights the conceptual evolution and methodological breakthroughs underpinning site- and stereoselective late-stage O-glycosylation. Recent innovations in transition-metal catalysis, organocatalytic activation, enzyme-mediated glycosyl transfer, and protecting-group-free tactics have expanded the synthetic toolbox, permitting precise glycosidic bond construction in densely functionalized settings. Case studies spanning anticancer anthracyclines, immunosuppressive macrolides, and antimicrobial glycopeptides illustrate how strategic glycosylation can reshape structure-activity relationships (SAR), improve therapeutic indices, and unlock access to glycoengineered analogues with superior drug-like profiles. Beyond synthetic utility, late-stage O-glycosylation provides a powerful lens through which chemical biology and medicinal chemistry converge. By transforming natural product frameworks into customizable molecular platforms, this strategy not only bridges the divide between synthetic innovation and translational drug discovery but also sets the stage for next generation glycomimetic therapeutics. Looking forward, integration of late-stage glycosylation with automated synthesis, chemoenzymatic platforms, and machine-learning-driven reaction design is poised to accelerate the discovery of tailor-made glycosylated drugs, cementing its role as a cornerstone of 21st-century molecular medicine.